Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
종목 코드 CUPR
회사 이름Cuprina Holdings (Cayman) Ltd
상장일Apr 10, 2025
CEOMr. Yong Qi (David) Quek
직원 수14
유형Ordinary Share
회계 연도 종료Apr 10
주소Block 1090
도시
증권 거래소NASDAQ Capital Market Consolidated
국가Singapore
우편 번호169201
전화6585127275
웹사이트https://cuprina.com/
종목 코드 CUPR
상장일Apr 10, 2025
CEOMr. Yong Qi (David) Quek
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음